Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Private placement and royalty agreement bring Nuron $80mm

Executive Summary

Nuron Biotech Inc. (vaccines) has raised $30mm in equity from first-time investor HealthCare Royalty Partners II. In addition to the private placement, HC Royalty has paid Nuron $50mm for royalty rights related to future sales of the company's Meningitec vaccine aimed at preventing invasive bacterial diseases caused by Neisseria meningitidis serogroup C, HibTiter Haemophilus influenza Type b conjugate vaccine, and Phase III NU100 for multiple sclerosis. Nuron acquired Meningitec from Pfizer earlier this month and HibTiter from the Big Pharma (which Pfizer got through its 2009 purchase of Wyeth) in April 2011. The $80mm will fund ongoing development of Nuron’s pipeline and also the commercialization of Meningitec. JMP Securities was the exclusive placement agent.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Other

Related Companies